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Abstract
We investigated association between HLA class I and class II alleles and haplotypes, and KIR loci 
and their HLA class I ligands, with multiple sclerosis (MS) in 412 European-American MS 
patients and 419 ethnically-matched controls, using next generation sequencing. The 
DRB1*15:01~DQB1*06:02 haplotype was highly predisposing (odds ratio (OR) = 3.98; 95% 
confidence interval (CI) = 3−5.31; p-value (p) = 2.22E−16), as was DRB1*03:01~DQB1*02:01 
(OR = 1.63; CI = 1.19–2.24; p = 1.41E−03). Hardy-Weinberg (HW) analysis in MS patients 
revealed a significant DRB1*03:01~DQB1*02:01 homozyote excess (15 observed, 8.6 expected; p 
= 0.016). The OR for this genotype (5.27; CI = 1.47–28.52; p = 0.0036) suggests a recessive MS 
risk model. Controls displayed no HW deviations. The C*03:04~B*40:01 haplotype (OR = 0.27; 
CI = 0.14–0.51; p = 6.76E−06) was highly protective for MS, especially in haplotypes with 
A*02:01 (OR = 0.15; CI = 0.04–0.45; p = 6.51E−05). By itself, A*02:01 is moderately protective, 
(OR = 0.69; CI = 0.54–0.87; p = 1.46E−03), and haplotypes of A*02:01 with the HLA-B Thr80 
Bw4 variant (Bw4T) more so (OR = 0.53; CI = 0.35–0.78; p = 7.55E−04). Protective associations 
with the Bw4 KIR ligand resulted from linkage disequilibrium (LD) with DRB1*15:01, but the 
Bw4T variant was protective (OR = 0.64; CI = 0.49–0.82; p = 3.37E−04) independent of LD with 
DRB1*15:01. The Bw4I variant was not associated with MS. Overall, we find specific class I 
HLA polymorphisms to be protective for MS, independent of the strong predisposition conferred 
by DRB1*15:01.
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1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with 
well-documented genetic contributions to its pathogenesis1. Genome wide association 
studies have implicated >100 loci in MS risk1. The strongest genetic associations with MS 
are with specific alleles at the HLA loci, in the Major Histocompatibility Complex (MHC) 
on chromosome 6p21. In particular, HLA-DRB1*15:01 is the strongest genetic determinant 
of MS; this association has been very well-established in a variety of studies and 
populations2–4. HLA-DRB1 allelic heterogeneity in MS risk has been described5–16, but the 
role of genetic variation at the other HLA loci has been less clearly defined, due, in part, to 
the extensive linkage disequilibrium (LD) among the alleles at these loci. The MHC includes 
~165 closely-linked genes, roughly half of which have immune-related functions17, and 
large-scale SNP screening of the MHC has identified at least one non-HLA MS association 
in the so-called class III region14. Using recently developed next generation sequencing 
(NGS) assays, we investigated the association of HLA class I and class II alleles with MS. 
NGS also facilitates the association analysis of the DRB3, DRB4 and DRB5 loci 
(DRB3/4/5). These loci display strong LD with specific DRB1 allele families18, and may 
modulate autoimmune disease associations attributed to the DRB1 locus19 and display 
DRB1-independent associations20, 21.
HLA disease associations are typically interpreted in terms of peptide binding and 
presentation driving specific adaptive immune responses, but class I epitopes serve as 
ligands for the killer immunoglobulin-like receptors (KIR) on natural killer (NK) cells, key 
elements in innate immunity22, 23 and possible contributors to MS pathogenesis. While the 
precise role of innate immunity in MS pathogenesis is unclear, NK cells may contribute to 
MS indirectly via immunoregulatory activity, or directly through cytotoxicity of self-
tissues24–27.
KIR epitope ligands are encoded by class I amino acid positions 77 and 80; variants at these 
positions define the HLA-C C1 and C2 ligands28, 29, the HLA-A A3/A11 ligand, and the 
Bw4 ligand of HLA-B and some HLA-A molecules30, 31. Encoded by genes on 19q13.4, 
inhibitory and stimulatory KIRs regulate the cytolytic killing and cytokine secretion of NK 
cells. The KIR gene complex is characterized by extensive gene content variation and allelic 
diversity; KIR haplotypes have been classified into two broad categories: KIR A (nine genes 
with primarily inhibitory functions) and KIR B (14 genes with inhibitory and stimulatory 
functions). The C1 ligand is recognized by the inhibitory KIR2DL2 and KIR2DL3 
receptors, C2 by KIR2DL129, Bw4 by KIR3DL132, and A3/11 by KIR3DL233. The 
stimulatory KIR2DS134, 35 and KIR2DS2 receptors are thought to bind to C2 and C1, 
respectively36; KIR2DS4 receptors bind strongly to A11 and weakly to C1 and C237.
KIR polymorphism has also been implicated in predisposition to many diseases, including 
MS38–43. The presence of Bw4, the ligand for KIR KIR3DL1, was protective for MS in a 
Norwegian cohort38 and, more recently, the combination of KIR3DL1 and Bw4 was 
protective in a study of African-American patients and controls44. Disease association 
analyses of KIR variation in the context of the HLA ligand require adjustment for LD 
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between the HLA ligands, and specific disease associated HLA alleles. Using a MALDI-
TOF mass spectrophotometer assay for KIR locus presence/absence and a NGS assay for 
HLA class I and class II alleles, we explored the association of specific KIR/HLA ligand 
combinations in a group of 412 patients of non-Hispanic European ancestry and 419 
ethnically matched controls. We address the confounding issue of LD in these association 
analyses using the strategy of stratification, analyzing those strata of the data in which an 
associated allele is present separately from those in which it is absent.
2. Results
We initially examined the association of alleles at individual HLA loci. Due to the very high 
LD between the DRB1 and DQB1 loci, and the HLA–C and –B loci, each locus pair 
(DRB1~DQB1 and C~B) haplotype was analyzed as a “super-locus” (Tables 1, 2, 3 and 
Supplementary Table S1). With the exception of DPB1, all loci and super-loci displayed 
significant locus level heterogeneity between MS patients and controls (Table 1).
2.1. HLA Class II Associations
Table 2 shows the association of DRB1~DQB1 haplotypes and of DPB1 alleles. As 
extensively documented in previous studies4, 45, 46, DRB1*15:01~DQB1*06:02 confers very 
high disease risk in this population (OR = 3.98; p-value (p) = <2.22E−16). We note that the 
other relatively common DR2 (including DR15 and DR16 alleles) haplotype in this 
population, DRB1*16:01~DQB1*05:02, does not confer MS risk (OR = 1.0; p = 0.95) in 
this dataset. Association studies of African-American populations, in which the LD patterns 
differ and the DQB1*06:02 allele is often found on non-DRB1*15 haplotypes, indicate that 
it is DRB1*15:01 and not DQB1*06:02 that confers MS risk44, 47. Given the strength of the 
DRB1*15:01 association with MS, all observed associations (class I alleles or HLA ligands) 
should be examined in light of potential LD with DRB1*15:01.
The other significantly associated susceptible DRB1~DQB1 haplotype in this dataset is 
DRB1*03:01~DQB1*02:01 (OR = 1.63; p = 1.41E−03), as previously reported5, 6. The 
DRB1*04:05, *08:01, and *13:03 alleles, previously reported to be associated with MS 7–16 
were not associated in this data set. DRB1*04:05 and *08:01 are found on haplotypes with 
different DQB1 alleles in European and East Asian populations. The low frequency of the 
DRB1*13:03~DQB1*03:01 haplotype in this data set (f = 0.014 in controls and 0.02 in 
cases) may explain the lack of statistical significance for this association (OR = 1.37; CI = 
0.6–3.19; p = 0.412). The frequency of DRB1*04:05 haplotypes was very low, and these 
haplotypes were “binned” (Supplementary Table S1). Counts, frequencies and summary 
statistics for all detected alleles and haplotypes are included in Supplementary Table S2.
DRB1*01:01~DQB1*05:01 (OR = 0.41; p = 9.57E−06), DRB1*04:01~DQB1*03:01 (OR = 
0.4; p = 1.24E−03), DRB1*14:01~DQB1*05:03 (OR = 0.42; p = 0.038) and 
DRB1*07:01~DQB1*02:02 (OR = 0.55; p = 0.0014) were significantly protective for MS. 
The DRB1*01:01~DQB1*05:01 haplotype is known to include the DQA1*01:01 allele48–52, 
which, along with DRB1*01:01, was recently shown to be protective for MS in the presence 
of DRB1*15:0153. While no DRB1~DQB1 haplotypes in our study displayed MS 
associations in the DRB1*15:01-positive stratum (Supplementary Table S3), 
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DRB1*01:01~DQB1*05:01 remained protective in the DRB1*15:01-negative stratum (OR 
= 0.57; p = 1.9E−02). The DRB1*14:01 protective effect has been previously reported54–56. 
No individual DPB1 alleles were associated with MS in this data set.
The clonal nature of NGS allows the analysis of the secondary DRB loci (DRB3/4/5). 
Because all DRB1*15:01~DQB1*06:02 haplotypes carried the DRB5*01:01 allele, and all 
DRB1*16:01~DQB1*05:02 haplotypes carried the DRB5*02:02 allele, the role of allelic 
variation at DRB5 could not be assessed in this dataset. However, the predisposing 
DRB1*03:01~DQB1*02:01 haplotype carries either DRB3*01:01 or *02:02. A recent study 
of type 1 diabetes19 showed that the DRB1*03:01 haplotypes carrying DRB3*02:02 
conferred greater risk than did those carrying DRB3*01:01. For MS, the allelic variation in 
DRB3, appeared to affect the risk conferred by DRB1*03:01 haplotypes based on this 
modest sample set (15 MS patients, 3 controls) but this effect was not significant. The OR 
for DRB1*03:01 homozygotes homozygous for DRB3*01:01 was 3.64 (CI = 0.69–36.1), 
whereas the OR for DRB1*03:01 homozygotes that carried DRB3*02:02 was 8.36 (CI = 
1.1–371.2). Testing whether the point estimates for these ORs are significantly different will 
require a larger sample set. We note that A*30:02 and B*18:01, alleles in strong LD with 
DRB1*03:01~DRB3*02:02 haplotypes19, are associated with MS (Table 3).
2.2. Protective Association of A*02:01
In the association analyses of the class I loci (Table 3), HLA-A*02:01 appears protective 
(OR = 0.69; p = 1.46E−03), as previously reported57–62. After stratifying the data to account 
for negative LD with DRB1*15:01 (Table 4), A*02:01 on haplotypes lacking DRB1*15:01 
remains protective (OR = 0.48; p = 1.1E−08).
Further, the ORs of three common extended A~C~B~DRB1~DQB1~DPB1 haplotypes, all 
bearing DRB1*15:01 and differing only in the HLA-A allele, indicate that the presence of 
A*02:01 can reduce the risk conferred by DRB1*15:01 (Table 5). The OR conferred by the 
extended C*07:02~B*07:02~DRB1*15:01~DQB1*06:02~DPB1*04:01 haplotype bearing 
A*02:01 is lower (OR = 1.65) than the OR for the same haplotype bearing A*03:01 (OR = 
2.83) or A*24:02 (OR = 4.48). This protective effect of A*02:01 is not simply a haplotype 
effect. The modification of DRB1-mediated risk by A*02:01 can also be assessed by 
stratifying the data based on the presence of A*02:01 (Table 6); these observations suggest 
that A*02:01 in cis or in trans can decrease the OR of other DRB1~DQB1 haplotypes.
2.3. Associated C~B haplotypes
For C~B haplotypes (Table 3), C*07:02~B*07:02 is associated strongly with MS (OR = 
1.99; p = 8.8E−07); however, this association reflects the strong LD between this haplotype 
and the predisposing DRB1*15:01 allele (d’ij = 0.71 in MS patients, and 0.52 in controls). 
Two different C~B haplotypes display a protective association in this data set. As previously 
reported60, 63, 64, C*05:01~B*44:02 is modestly protective (OR = 0.65; p = 0.043). B*44:02 
is rarely found with any other HLA-C allele, while the C*05:01~B*18:01 haplotype is 
clearly not protective (OR = 2.07; CI = 0.88–5.25; p = 0.71), suggesting that B*44:02 may 
be responsible for the observed modest association for this haplotype.
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In addition, the C*03:04~B*40:01 haplotype (OR = 0.27; p = 6.76E−06) shows a strong 
protective association. This protective C~B haplotype is in LD with the protective A*02:01 
allele, and this three-locus haplotype (Table 4) is even more strongly protective (OR = 0.15; 
CI = 0.04–0.45; p = 6.5E−05).
The cALD measures WHLA-A/HLA-C~HLA-B and WHLA-C~HLA-B/HLA-A are 0.6 and 0.42 in 
cases, and 0.6 and 0.39 in controls, respectively, indicating more variation of C~B 
haplotypes relative to HLA-A alleles, than in HLA-A alleles relative to C~B haplotypes; the 
intermediate level of LD between A*02:01 and the C*03:04~B*40:01 haplotype (d’ij = 0.11 
in MS patients and 0.34 in controls) suggests that the strong protective association for the 
A*02:01~C*03:04~B*40:01 haplotype results from the combination of these three alleles, 
and not LD with a single protective locus. C*03:04~B*40:01 remains protective in the 
absence of A*02:01 (OR = 0.42; p = 0.018), and A*02:01 is modestly protective in the 
absence of C*03:04~B*40:01 (OR = 0.79; p = 0.048), suggesting that the observed 
protective association for the A*02:01 allele is not due entirely to LD with 
C*03:04~B*40:01.
2.3.1. Impact of DRB1*15:01 Predisposition on C*03:04~B*40:01 Association—
The highly protective C*03:04~B*40:01 haplotype is in negative LD with the highly 
predisposing DRB1*15:01 allele (d’ij = -1); no C*03:04~B*40:01-bearing haplotypes carry 
DRB1*15:01. In principle, this negative LD with DRB1*15:01 might account for the 
protective associations observed for A*02:01 and C*03:04~B*40:01. We applied 
stratification analyses (Table 4) to determine if this LD pattern could account for the 
observed protective association of this C~B haplotype. In the stratum lacking DRB1*15:01, 
the protective association of C*03:04~B*40:01 is even stronger (OR = 0.29; CI = 0.15–0.55; 
p = 2.45E−05), so the protective association cannot be attributed simply to negative LD with 
the highly predisposing DRB1*15:01. In individuals carrying DRB1*15:01, the presence of 
the C*03:04~B*40:01 haplotype on the other chromosome reduces MS risk (OR = 1.37; p = 
0.57) compared to all other C-B haplotypes (OR = 5.06; p = 3.21E−13) (Table 6). The only 
other significant associations in this DRB1*15:01-negative stratum are C*05:01~B*18:01 
(OR = 2.87; p = 0.01) and C*07:01~B*08:01 (OR = 1.98; p = 0.0004) but these are both due 
to LD with the predisposing DRB1*03:01 (d’ij = 0.87 and 0.72 in cases, and 0.51 and 0.69 
in controls, respectively). C*03:04~B*40:01 remained protective in the DRB1*03:01-
negative stratum (OR = 0.32) (data not shown).
2.4. Hardy-Weinberg Equilibrium Analyses
The analysis of Hardy-Weinberg equilibrium (HWE) among controls can serve as a test of 
genotyping and sampling validity, while deviations from HWE among cases can, potentially, 
reveal patterns of disease association. Adherence to HWE expectations is a requirement for 
control groups in case-control studies. Among those loci that showed a significant MS 
association (HLA-A, -B, -C, DRB1, DQB1), no deviation from HWE was observed among 
controls (data not shown), including HWE analysis for DRB1~DQB1 haplotypes. While 
studies of HLA diversity in the US population have identified varying degrees of population 
stratification among non-Hispanic European Americans65, 66, these Hardy-Weinberg 
analyses reveal no significant population stratification in this cohort.
Mack et al. Page 5
Genes Immun. Author manuscript; available in PMC 2019 April 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Among MS patients, highly significant deviations from HWE were seen for genotypes of 
DR~DQ haplotypes (p = 0.0027). The two most common genotypes of DRB1~DQB1 
haplotypes that contributed to this deviation were DRB1*03:01~DQB1*02:01 homozygotes 
(15 observed, 8.6 expected; p = 0.016) and 
DRB1*07:01~DQB1*03:03+DRB1*15:01~DQB1*06:02 heterozygotes (10 observed, 5.3 
expected; p = 0.0078), both observed more often than expected among cases. The excess of 
DRB1*03:01 homozygotes among cases suggests a recessive model for MS risk. Consistent 
with this interpretation of the HWE deviation, the OR for the homozygous 
DRB1*03:01~DQB1*02:01 genotype is 5.27 (p = 0.0037) compared to 
DRB1*03:01~DQB1*02:01+DR~DQ*X (OR = 0.74; p = 0.13), where DR~DQ*X is any 
haplotype that does not include DRB1*15:01 or DRB1*03:01. The OR for this 
DRB1*03:01~DQB1*02:01 homozygote is close to that for 
DRB1*03:01~DQB1*02:01+DRB1*15:01~DQB1*06:02 (OR = 5.55; p = 1.32E−06) and 
DRB1*15:01~DQB1*06:02+DRB1*15:01~DQB1*06:02 homozygote (OR = 7.6; p = 1.13E
−05).
The excess of observed DRB1*07:01~DQB1*03:03+DRB1*15:01~DQB1*06:02 genotypes 
among cases suggests that the susceptibility conferred by the DRB1*15:01 haplotype may 
be “dominant” over the protection conferred by the DRB1*07:01 haplotype. The expected 
number of cases in the HWE analysis is based on the protective effect of the 
DRB1*07:01~DQB1*03:03 haplotype over all genotype combinations.
2.5. Association analysis of KIR and HLA ligands
2.5.1 HLA Ligands—Association analyses for the presence/absence of the KIR loci and 
their HLA ligands are shown in Table 7 and Supplementary Table S4. As previously 
reported38 the HLA ligand Bw4 (Thr or Ile at HLA-B amino-acid position 80) is negatively 
associated with MS (Table 7A; OR = 0.62; p = 5.95E−04). The OR for Bw4/Bw4 is 0.63 and 
for Bw6/Bw6 is 1.61. The observed protective effect of Bw4+ alone, however, may be 
attributed, in part, to negative LD with the highly predisposing DRB1*15:01; when the data 
are stratified on the presence of DRB1*15:01 (Table 7B), the statistical significance of the 
Bw4+ effect is diminished in the stratum missing DRB1*15:01 (OR = 0.72; p = 0.08). This 
interpretation suggests that the observed Bw4 protective association with MS is not 
necessarily due to the Bw4 signaling via its inhibitory receptor KIR3DL1, but may simply 
reflect LD patterns between HLA-B and DRB1.
In the association analysis of individual amino acid residues (see below, Table 8C), the Bw4 
epitope with Thr at position 80 (Bw4T) shows a protective association (OR = 0.64; p = 
0.0003) but the stronger-binding Bw4 epitope with Ile (Bw4I) does not (OR = 0.92; p = 
0.56), consistent with the Bw4 association reflecting LD and not ligand mediated KIR 
signaling. Association analyses of the Bw4 epitope on some HLA-A molecules (ABw4) 
reveal no protective effect (data not shown). The frequency of DRB1*15:01 in Bw4+ 
individuals is 48% in MS patients and 16% in controls, while it is 51% in Bw4- patients and 
26% in Bw4- controls, suggesting that the disease risk associated with DRB1*15:01 is not 
reduced in the Bw4 positive stratum. However, subdividing Bw4 does reveal a difference in 
the association pattern, and this difference cannot be attributed simply to LD. Both Bw4T 
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and Bw4I are in negative LD with DRB1*15:01 (d’ij = -0.45 and -0.64 in cases, and -0.79 
and -0.92 in controls, respectively) but the negative association of Bw4T with MS remains 
nominally significant (OR = 0.071; p = 0.032) even in the DRB1*15:01 negative stratum 
(Table 7C).
2.5.2 HLA Ligand with KIR—Since the interaction of specific receptors and their HLA 
ligands is functional, we analyzed specific combinations of HLA ligands and KIR genotypes 
(Supplementary Table S4A). To address the issue of LD with DRB1*15:01, we also 
examined these combinations in the stratum lacking DRB1*15:01 (Supplementary Table 
S4B). The combination of Bw4 and KIR3DL1 has been reported to be protective in the 
recent study of MS in African-Americans44 including the DRB1*15:01-lacking stratum. In 
our dataset, Bw4 is protective in the presence of KIR3DL1, a gene present on virtually all 
KIR haplotypes (OR = 0.62; p = 6.12E−04) but also protective in the presence of KIR2DL3 
(OR = 0.58; p = 9.12E−05). However, following stratification on DRB1*15:01, Bw4 and 
KIR3DL1 are no longer significantly protective (OR = 0.75; p = 0.11) in the DRB1*15:01 
negative stratum. The protective association with Bw4 and KIR2DL3, however, is still 
nominally significant (OR = 0.62; p = 0.010). At the KIR genotype level, one specific 
combination in this DRB1*15:01 negative stratum (Bw4+ and KIR2DL2/KIR2DL3) shows 
a nominally significant protective association (OR = 0.59; p = 0.017), but Bw4+ with 
KIR2DL2/KIR2DL2 (OR = 2.17; p = 0.051), or with KIR2DL3/KIR2DL3 (OR = 0.91; p = 
0.63) do not. Given the multiple comparisons in this association analysis, replication in 
another cohort will be critical in validating this observation.
2.6. Association Analyses of Individual Amino Acids
The association analyses of individual amino acids in the HLA class I and class II genes can 
potentially reveal functionally important aspects of disease associations. Several statistically 
significant associations are shown in Table 8A and dissected in Tables 8B and 8C.
Table 8B shows the individual DRB1 exon 2-encoded amino acid residues associated with 
MS. Pro at DRβ position 11 and Arg at position 13 are significantly associated with MS (OR 
= 3.23; p = 2.22E−16, each) but these specific residues are unique to DRB1*15 and *16 
alleles and reflect the association of DRB1*15:01. The less common DRB1*15:02 and 
DRB1*16:01 alleles found in this population share this amino acid motif but do not confer 
risk to MS. Position 86 Val is also associated with MS (OR = 2.15; p = 1.56E−14). Many 
DRB1 alleles that are not associated with MS also encode Val-86 but the Val-Gly 
dimorphism at position 86 is the only difference between highly susceptible DRB1*15:01 
and neutral DRB1*15:02. Position 86 contributes to peptide binding pocket 1, underscoring 
the role of position 86 dimorphism in determining peptide specificity.
Association analyses of individual HLA class I-encoded amino acid residues that constitute 
the KIR ligand epitopes are shown in Table 8C. As noted above, the HLA-B position 80 
Bw4T subtype is protective while Bw4I, thought to be a stronger binding ligand of 
KIR3DL1, is not. The modest protective association of Bw4T is not due to negative LD with 
DRB1*15:01, as it remains nominally significant even in the DRB1*15:01-negative stratum 
(Table 7C).
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The HLA-C positions 77 and 80, which encode the C1 and C2 KIR ligands, are not 
associated with MS but, interestingly, amino acid positions 73–90, which influence the 
strength of KIR ligand binding67 are significantly associated. The OR for the 73-77-80-99 
motif (A~S~N~D) for the C2 epitope is 1.63 (p = 2.3E−06). This motif, however is in LD 
with HLA-C*07:02 (OR = 1.9; p = 2.11E−06), the HLA-C allele in LD with DRB1*15:01. 
Thus, the observed association of the A~S~N~D C2 motif probably reflects LD rather than 
KIR signaling. The same motif is present in C*07:01 and *07:04, alleles not associated with 
MS, consistent with this interpretation.
2.7 HLA-A*02:01 and Bw4
The strong protective associations of C*03:04~B*40:01 and A*02:01 do not appear to 
reflect LD with DRB1*15:01 or the Bw4 ligand group. The A*02:01 protective association 
with MS has been previously reported in various populations14, 57–61. In a recent study of 
African-American MS, the combined presence of KIR3DL1 and Bw4, its ligand, was 
protective, and the protective association for A*02 was attributed to LD with Bw444. This 
interpretation suggests that innate immunity and NK cell function, regulated by the Bw4 
ligand, account for the observed negative association with A*02:01.
Our data suggest that A*02:01 is associated with protection from MS in European 
Americans, and that the protection conferred by A*02:01 in combination with 
C*03:04~B*40:01 (OR = 0.15; p = 6.51E−05) is stronger than the observed negative 
association with Bw4 presence (OR = 0.62; p = 5.95E−04). In our study, LD is modest 
between A*02:01 and the Bw4 epitope (d’ij = 0.17 in MS patients and 0.18 in controls), but 
much lower than LD of C*07:02~B*07:02 with DRB1*15:01 in MS patients (0.71) or 
A*02:01 with C*03:04~B*40:01 in controls (0.34). The A*02:01~Bw4 haplotype is as 
protective as Bw4 presence (OR = 0.62; p = 1.69E−03) (Table 9), but A*02:01~Bw4T 
haplotypes are more protective (OR = 0.53; p = 7.55E−04), while A*02:01~Bw4I 
haplotypes are not, consistent with Table 8C.
LD between A*02:01 and Bw4T is comparable to that between A*02:01 and Bw4 (d’ij 0.16 
in MS patients and controls), whereas LD is much stronger between A*02:01 and 
C*05:01~B*44:02 (0.59 in MS patients and 0.62 in controls). Of the HLA-B alleles in 
protective C~B haplotypes, B*40:01 encodes Bw6, while B*44:02 encodes Bw4T; the 
protection associated with Bw4T may reflect, in part, the protective C*05:01~B*44:02 
haplotype (and perhaps other Bw4T-encoding HLA-B alleles).
3. Discussion
We have identified multiple HLA class I and class II alleles and haplotypes associated with 
MS. Strong LD is a characteristic of the HLA region, and we investigated allele-pair LD and 
conditional asymmetric LD, and applied stratification analysis to adjust for LD in order to 
dissect and interpret these associations. In addition to standard case-control association 
analyses, we applied Hardy-Weinberg equilibrium analyses to cases and controls to validate 
our association findings. Many immune-related genes in the MHC were not analyzed in this 
study; given the LD known for the MHC, our analyses do not exclude these genes as 
potentially playing roles in MS susceptibility. However, association analysis, following 
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stratification, proved effective at identifying the independent effects of specific HLA alleles 
and haplotypes. As reported in many previous studies, the DRB1*15:01~DQB1*06:02 
haplotype is most strongly associated with MS risk; DRB1*03:01~DQB1*02:01 is also 
significantly associated with a recessive effect on MS risk and, as expected, is very strongly 
associated with MS in the DRB1*15:01-negative stratum. NGS HLA typing allowed the 
analysis of the DRB3 allelic diversity on DRB1*03:01 haplotypes, and our analyses suggest 
that DRB3*02:02 may confer higher risk than DRB3*01:01, but this observation must be 
tested in a larger study.
A*02:01, C*03:04~B*40:01 and the haplotype carrying all three alleles show very strong 
protective associations (OR = 0.15 for the three-locus haplotype) with MS, independent of 
LD with DRB1*15:01. The protective association of the A*02:01~C*03:04~B*40:01 
haplotype displays the strongest effect size of the observed HLA associations in this study.
For the HLA ligands of the KIR, the presence of Bw4 was negatively associated with MS in 
the unstratified dataset, as noted in previous reports, but was no longer significant in the 
stratum lacking DRB1*15:01. While this observed association may simply reflect negative 
LD between Bw4 and DRB1*15:01 in this population, the two Bw4 subtypes, Bw4T and 
Bw4I, showed different association patterns. The protective association of Bw4T remained 
nominally significantly even in the DRB1*15:01-negative stratum, while Bw4I was not 
associated in either stratum. The Bw4 motif on HLA-A molecules (all of which are Bw4I) 
was also not significantly protective. From the available data, we cannot distinguish between 
a potential effect on peptide binding mediated by this Thr/Ile polymorphism in HLA-B 
pocket F, differential signaling via the KIR3DL1 receptor, or a combination of the two. A 
recent study of HIV infection indicates that the binding of a specific HIV peptide can 
influence the interaction of the Bw4 epitope with the KIR3DL1 receptor68. The difference 
between an uncharged, polar side chain (Thr) and an aliphatic side chain (Ile) may influence 
peptide binding, and through differential peptide binding, KIR3DL1 signaling.
In investigating different HLA ligand/KIR genotype combinations in the DRB1*15:01-
negative stratum, the strongest protective Bw4 association we observed was in combination 
with KIR2L2/KIR2DL3, which is stronger than Bw4 in combination with 3DL1. This 
protective association was nominally significant but, given the number of comparisons, 
validation of this observation requires testing in another large cohort. The immunological 
mechanism underlying the Bw4 T protective association remains unclear.
Many other amino acid positions were implicated in our analyses, but, as in all HLA related 
association studies, they must be considered in the context of LD. Some disease associated 
amino acid residues simply “tag” an allele, recapitulating an already well-established allele 
association. These associations, the report of Raychaudhuri and colleagues 
notwithstanding69, do not increase our functional understanding of HLA-related disease 
association. However, other individual amino acid associations that do not correspond 
uniquely to specific alleles may provide some functional insights, although the peptide 
binding properties of HLA molecules are obviously determined by multiple amino acid 
residues. In general, the potential role of individual amino acids in disease associations can 
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be best evaluated by comparing alleles that differ in disease risk, and differ in only one 
amino acid position.
For example, DRB1 alleles encode either Gly or Val at DRβ position 86; this position 
contributes to peptide binding pocket 170, which anchors the N-terminal end of the bound 
peptide71. Positions 82 and 89 also contribute to pocket 1, but are invariant in this dataset 
and in most HLA alleles. Neither 86G nor 86V tag a specific allele, but the predisposing 
DRB1*15:01 allele (86V) and the neutral DRB1*15:02 allele (86G) differ only at encoded 
position 86. In Table 8B, position 86V (OR = 2.15; p = 1.56E−14) was implicated as 
potentially being functionally related to the observed association of DRB1 with MS.
Finally, the non-Hispanic European-American cohort in this study represents a “pan-
European” population, and as such may be subject to population stratification. However, our 
Hardy-Weinberg analyses revealed no significant population stratification in this cohort. In 
addition, the frequencies of key alleles and haplotypes (e.g., HLA-B*18:01 and the 
A1~B8~DR3 haplotype) in our cohort are consistent with those observed across Europe72, 
as opposed to the very high-frequencies observed for these variants in specific European 
populations, again suggesting that stratification in this cohort is minimal.
3.1 Conclusions
Some associations of specific HLA alleles, e.g., the strong protective effect of the 
C*03:04~B*40:01 haplotype, remain highly significant following stratification on 
DRB1*15:01. In general, the results of these analyses indicate that a careful consideration of 
LD patterns among HLA alleles is essential in the interpretation of MS association data. 
Overall, we conclude that specific HLA class I polymorphisms are protective for MS, 
independent of the strong MS predisposition conferred by the DRB1*15:01 allele.
4. Materials and Methods
4.1 Samples
Blood samples were collected for 412 MS patients of self-identified non-Hispanic European 
ancestry, and 419 healthy, ethnically matched controls. MS patients were diagnosed by 
neurologists specialized in demyelinating diseases in accordance with well-established 
diagnostic and study inclusion criteria73. Controls were of self-identified non-Hispanic 
European ancestry and reported no history of chronic diseases for themselves or their 
nuclear family. De-identified genomic DNA was extracted using a standard desalting method 
and quantitated in duplicate using the PicoGreen dsDNA quantitation reagent. Coded DNA 
aliquots are stored at −80°C. Study protocols were approved by the UCSF Committee on 
Human Research and informed consent was obtained from all participants.
4.2 Genotyping
Locus-specific genotyping for the 14 KIR loci was performed as previously described74, 75. 
Next-generation sequencing of HLA-class I exons 2, 3 and 4, HLA class II exon 2, and HLA 
class II exon 3 (for the DQB1 locus) on the Roche (Pleasanton, CA, USA) 454 GS FLX 
instrument was used to genotype HLA-A, -C, -B, DRB1, DRB3/4/5, DQA1, DQB1 and 
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DPB1 alleles76–79. NGS HLA sequences were assigned to HLA alleles on the basis of 
reference sequences in IMGT/HLA Database version 3.1.0 (July 17, 2010) using Conexio 
(Fremantle, Australia) Assign ATF version 1.1.0.35.
HLA genotyping was blinded with respect to MS patients and controls, with 15% of 
specimens retyped for quality assurance purposes; our NGS HLA genotypes were verified 
independently via HistoGenetics (Ossning, NY, USA)80 with >98% concordance. 
Discordant typings were reviewed and re-typed, and the final dataset was 100% concordant 
between the two NGS methods. Subject disease-status (case/control) was only released for 
analysis after the genotyping was completed.
4.3 Data Analysis
4.3.1. Tests of Association—We applied locus-level tests of heterogeneity and variant-
level chi-squared (χ2) tests of association at the genotype, haplotype, locus and individual 
amino acid levels using BIGDAWG (v1.8.1)81. In these tests, each multi-gene group (e.g., 
HLA-C~HLA-B), individual gene (e.g., HLA-DRB1) and inferred polymorphic amino acid 
position (e.g., DRβ position 86) was treated as a locus, and individual haplotypes (e.g., 
HLA-C*07:02~HLA-B*07:02), alleles (e.g., DRB1*03:01) and amino-acid residues (e.g., 
DRβ position 86V) were treated as variants. For each comparison, variants with expected 
counts less than 5 in cases or controls were combined into a common “binned” category for 
analyses82.
We measured interaction between KIR and HLA loci by applying a χ2 test to contingency 
tables that crossed disease phenotype with genotype, where genotype was defined as a given 
KIR-HLA combination. Specifically, we tested dominant and additive effects of KIR genes 
and their ligands at all biallelic loci in the overall cohort in addition to sub-cohorts defined 
by presence of DRB1*15:01. From these contingency tables, we calculated odds ratio with 
95% confidence intervals, and p-values.
4.3.2. Test of Hardy-Weinberg Equilibrium—We performed tests for deviations from 
Hardy-Weinberg equilibrium (HWE) proportions using BIGDAWG and PyPop (v0.7.0)83, 
assessing genotyping proportions for both individual loci and specific haplotypes (using 
haplotypes assigned to individuals in BIGDAWG on the basis of posterior probabilities). We 
identified significant locus-level HWE deviations using Guo and Thompson’s exact 
method84, and identified individual genotypes deviating significantly from HWE 
expectations using Chen’s method85, 86, using a threshold of significance of 0.05.
4.3.3. Evaluation of Linkage Disequilibrium—We calculated normalized LD values 
(d’ij)87 for individual haplotypes with PyPop, and calculated conditional asymmetric LD 
(cALD) values, evaluating LD between sets of loci, using the “asymLD” R package (v0.1)88. 
Values of d’ij range from -1, when the haplotype is never observed, to 1, describing the 
maximum possible LD based on the frequencies of the constituent alleles. The cALD 
measure WA/B is the correlation coefficient for alleles at locus A conditioned on the alleles 
at locus B, and describes the overall variation of alleles at locus A, given specific alleles at 
locus B. WB/A is the correlation coefficient for alleles at locus B, conditioned on the alleles 
at locus A, and describes the overall variation of alleles at locus B, given specific alleles at 
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locus A89. When there are equal numbers of alleles and complete allele correlation between 
both loci, the value of WA/B and WB/A is 1, indicating no variation of alleles between loci.
4.3.4. Corrections for Multiple Comparisons—For locus-level χ2 tests of 
heterogeneity involving individual loci (i.e., HLA-A and DPB1) and haplotypes of loci (e.g., 
C~B and DRB1~DQB1), the threshold of significance was calculated as 0.05/n, where n is 
the number of comparisons. We note that these comparisons are not necessarily independent 
(e.g., the HLA-A locus is included in four comparisons), so that these estimates can be 
considered overly conservative.
Our tests of the specific hypothesis that the protective effect of HLA-A*02:01 is due to LD 
with the Bw4 motif44 are addressed separately from other locus-level and haplotype-level 
comparisons. These tests pertained to the A~Bw4/Bw6 and A~HLA-B Position 80 amino-
acid variant haplotypes. Similarly, our tests of Bw4 Thr and Ile subtypes in DRB1*15:01-
positive and –negative strata address our observation that HLA-B position 80T is associated 
with MS, whereas position 80I is not, and our tests of DRB1 alleles in DRB1*15:01-positive 
and –negative strata address the observation that DQA1*01:01 (found on the 
DRB1*01:01~DQB1*05:01 haplotype) is protective only in the presence of DRB1*15:0153. 
The threshold of significance for both of these pairs of locus-level χ2 tests of heterogeneity 
was calculated as 0.05/2 (0.025E−2).
For χ2 tests of heterogeneity of amino-acid positions, the threshold of significance was 
calculated for each individual locus as 0.05/n, where n is the number of variant amino-acid 
positions at that locus. Results are not presented for positions that did not display significant 
position-level heterogeneity.
In cases where locus-level tests of heterogeneity were not significant (p-value > the 
threshold of significance), the threshold of significance for the χ2 tests of association was 
calculated as 0.05/n, where n equals the number of variants at that locus.
4.3.5. Statistical Power Analysis—We used the pwr.chisq.test function in the R “pwr” 
package (version 1.2–0) to evaluate the size of an effect detectable in our dataset with the 
recommended statistical power (1-β) of 0.8 with an α of 0.0590. For association tests of 
alleles and haplotypes, with 31 allele categories, we expect to detect small effect sizes 
(0.121). For tests of locus presence, motifs and amino acid positions, with 2–5 categories, 
we expect to detect very small effect sizes (0.068 – 0.085).
4.4. Data Access
The HLA and KIR genotype data used for the analyses described here have been deposited 
into ImmPort (http://www.immport.org), the public data-sharing resource of the National 
Institute of Allergy and Infectious Disease’s (NIAID) Division of Allergy, Immunology, and 
Transplantation (DAIT) and Division of Microbiology and Infectious Diseases (DMID), and 
can be accessed under the ImmPort Study Accession Number SDY1045 (doi:10.21430/
M3QW34U2SG).
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4.5 Code Availability
The source code for BIGDAWG is available online at https://cran.r-project.org/web/
packages/BIGDAWG/index.html and https://github.com/IgDAWG/BIGDAWG, with version 
1.8.1 code at https://github.com/IgDAWG/BIGDAWG/tree/
eb0b4140ec3fb85b1a4fba5826ffc9f9e3239d10.
The source code for asymLD v0.1 is available online at https://cran.r-project.org/web/
packages/asymLD/index.html.
The source code for PyPop is available online at https://github.com/alexlancaster/pypop, 
with version 0.70 code at https://github.com/alexlancaster/pypop/tree/
3f29d4b53548ce4deb60a5960368627999396653.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Locus-level Heterogeneity between Multiple Sclerosis Patients and Controls
Locus χ2 d.f. p-value Significance 1
A 43.3012 17 4.34E−04 *
A~DRB1 169.5478 38 < 2.22E−16 *
A~DRB1~DQB1 161.7085 39 < 2.22E−16 *
A~C~B~DRB1~DQB1~DPB1 42.5118 11 1.3205E−05 *
C~B 81.8819 33 4.9007E−06 *
C~B~DRB1 100.52 24 2.45E−11 *
DRB1~DQB1 159.1034 26 < 2.22E−16 *
DPB1 21.061 15 1.35E−01 NS
χ2: Chi-squared value.
d.f.: Degrees of freedom.
1After correcting for eight comparisons, significance was evaluated at the 6.25E−03 level. Significant p-values are indicated with asterisks. NS: Not 
Significant.
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